SCHEMBL20109993

SCHEMBL20109993

c1ccc(-c2ccc(-c3ccc(-c4ccccc4)c4oc5ccc(-c6c7ccccc7c(-c7ccccc7)c7ccccc67)cc5c34)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC14B O60729 2/20 0.41
▸ CDC14A Q9UNH5 2/20 0.41
▸ PLA2G2A P14555 4/20 0.40
▸ PLA2G4A P47712 4/20 0.40
▸ PIM1 P11309 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ PIM3 Q86V86 1/20 0.39
▸ PIM2 Q9P1W9 1/20 0.39
▸ WEE1 P30291 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ CDK1 P06493 3/20 0.36
▸ CCNB1 P14635 3/20 0.36
▸ CCNE1 P24864 3/20 0.36
▸ CDK2 P24941 3/20 0.36
▸ CCNE2 O96020 2/20 0.36
▸ GSK3B P49841 2/20 0.36
▸ CDK5 Q00535 2/20 0.36
▸ CDK5R1 Q15078 2/20 0.36
▸ PLA2G10 O15496 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20109987 0.98 CDC14B (0.42) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL26774399 0.90 CDC14B (0.37) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL25624537 0.89 CDC14B (0.45) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL26774247 0.88 CDC14B (0.38) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL18382914 0.88 CDC14B (0.51) CDC14BCDC14APLA2G2APLA2G4AALOX5
SCHEMBL23504687 0.87 CDC14B (0.44) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL23504689 0.87 CDC14B (0.44) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL18382824 0.87 CDC14B (0.37) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL25588897 0.85 ALOX5 (0.41) CDC14BCDC14APLA2G2APLA2G4APIM1
SCHEMBL19770496 0.85 ALOX5 (0.50) CDC14BCDC14APLA2G2APLA2G4APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240023359-A1 ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER SFC CO., LTD. (KR) 2024-01-18 — — US disclosed
US-20230371376-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME SFC CO., LTD. (KR) 2023-11-16 — — US disclosed
US-20180123055-A1 COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME SFC CO., LTD. (KR) 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230371376-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME PPOX, MAP1LC3A, VDAC2 CDC14B 2715/4885CDC14A 2656/4885PLA2G2A 1893/4885
US-20180123055-A1 COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME CYP1B1, CYP1A1, CRY2 CDC14B 3005/4885CDC14A 3078/4885PLA2G2A 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback